Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

First Human Trial of Off-the-Shelf CAR T-Cell Therapy Shows Promise

Last month at the virtual annual meeting of the American Association for Cancer Research (AACR), Chinese researchers announced results from the first human trial...
On location

MLL Associated With Worse Post-Transplant Outcomes Than Other Cytogenetic Factors

In an analysis comparing the effects of MLL translocations with other cytogenetic characteristics on post-transplant outcomes in acute myeloid leukemia (AML), investigators found that...

Venetoclax Plus High-Dose Cytarabine With or Without Idarubicin Well Tolerated in Pediatric AML

In a small study of children and young adults with relapsed or refractory acute myeloid leukemia (AML), venetoclax plus cytarabine chemotherapy, with or without...

Putting Mutation Testing in Myeloid Malignancies to the Test

In 2014, the World Health Organization (WHO) convened a clinical advisory committee to begin updating and revising the existing classification of myeloid neoplasms (MPNs)...

Emerging Opportunities: Reevaluating Maintenance Therapy in AML

The concept of maintenance therapy in acute myeloid leukemia (AML) is not new. But for decades, research was unable to show any clear survival...

Venetoclax Plus Low-Dose Cytarabine Improves Survival and Remission in Patients With Chemotherapy-Ineligible AML

Treatment with venetoclax plus low-dose cytarabine (LDAC) led to greater improvements in remission and overall survival (OS), compared with LDAC alone, in patients with...

2017 European LeukemiaNet Risk Groups Predict Prognosis in FLT3-ITD AML

Genetic risk groups defined by the 2017 European LeukemiaNet (ELN) recommendations may reliably predict prognosis in patients with acute myeloid leukemia (AML) and internal...

Aveo and Biodesix Stop Trials of Ficlatuzumab for Acute Myeloid Leukemia

Aveo and Biodesix have decided to stop all trials of their hepatocyte growth factor inhibitory antibody ficlatuzumab for acute myeloid leukemia (AML), citing the...

Can Dasatinib Overcome the Negative Effects of KIT Mutations in Core Binding Factor AML?

A chemotherapy regimen of cytarabine and daunorubicin plus dasatinib was well tolerated in patients with previously untreated core binding factor acute myeloid leukemia (CBF-AML)...
WIB_icon

Germline RUNX1 Mutations in RUNX1-Mutated AML More Frequent Than Previously Thought

A small study in Canada shows that the frequency of germline RUNX1 mutations in patients with RUNX1-mutated acute myeloid leukemia (AML) is higher than...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.